サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1720007

院内感染治療薬市場：薬剤タイプ別、投与経路別、感染タイプ別、国別、地域別 - 産業分析、市場規模、市場シェア、予測（2025年～2032年）

Hospital Acquired Infections Therapeutic Market, By Drug Type, By Route of Administration, By Infection Type, By Country, and By Region: Industry Analysis, Market Size, Market Share, and Forecast from 2025 to 2032

出版日
ページ情報
英文 396 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
院内感染治療薬市場：薬剤タイプ別、投与経路別、感染タイプ別、国別、地域別 - 産業分析、市場規模、市場シェア、予測（2025年～2032年）
出版日: 2025年03月25日
発行: AnalystView Market Insights
ページ情報: 英文 396 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

院内感染治療薬の市場規模は2024年に138億7,500万米ドルとなりました。同市場は、2025年から2032年にかけて3.70%のCAGRで拡大すると予測されています。

院内感染とは、入院中に発症し、入院前には発症していなかった感染症のことです。院内感染対策とは、さまざまな洗浄、滅菌、消毒技術による院内感染の予防と制御を指します。これらの感染症は、器具の表面、患者の皮膚、ヘルスケアスタッフの二次汚染によって引き起こされる可能性があります。病院における感染管理は、疾病の伝播を減少または排除するために行われます。

当レポートでは、世界の院内感染治療薬市場について調査し、市場の概要とともに、薬剤タイプ別、投与経路別、感染タイプ別、国別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 院内感染治療薬市場概要

第2章 エグゼクティブサマリー

  • 市場内訳
    • 院内感染治療薬市場内訳（薬剤タイプ別）
    • 院内感染治療薬市場内訳（投与経路別）
    • 院内感染治療薬市場内訳（感染タイプ別）
    • 院内感染治療薬市場内訳（国別）
    • 院内感染治療薬市場内訳（地域別）
  • 競合考察

第3章 院内感染治療薬の主要市場動向

  • 院内感染治療薬市場の促進要因
  • 院内感染治療薬市場の抑制要因
  • 院内感染治療薬市場の機会
  • 院内感染治療薬市場の将来動向

第4章 院内感染治療薬産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 院内感染治療薬市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 院内感染治療薬市場情勢

  • 院内感染治療薬市場シェア分析（2024年）
  • 主要メーカー別内訳データ
    • 老舗企業の分析
    • 新興企業の分析

第7章 院内感染治療薬市場- 薬剤タイプ別

第8章 院内感染治療薬市場- 投与経路別

第9章 院内感染治療薬市場- 感染タイプ別

第10章 院内感染治療薬市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 米国
    • カナダ
  • 欧州
    • 概要
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 院内感染治療薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Merck & Co.
    • Abbott
    • F. Hoffmann-La Roche
    • AbbVie
    • Allergan Plc
    • Eugia Pharma
    • Bayer
    • DAIICHI SANKYO COMPANY
    • Glenmark Pharmaceuticals
    • GSK
    • Hikma Pharmaceuticals
    • Melinta Therapeutics
    • Pfizer
    • Sanofi
    • Viatris
    • その他

第12章 360度アナリストビュー

第13章 付録

目次
Product Code: ANV5006

REPORT HIGHLIGHT

Hospital Acquired Infections Therapeutic Market size was evaluated at USD 13,875 million in 2024, rising at a CAGR of 3.70% between 2025 and 2032.

Hospital-acquired infections are infections that develop during hospitalisation that were not present before admission. Hospital-acquired infection control refers to the prevention and control of hospital-acquired infections through various cleaning, sterilisation, and disinfection techniques. These infections can be caused by cross-contamination of equipment surfaces, patient skin, and healthcare staff. Infection control in hospitals is used to reduce or eliminate disease transmission.

Hospital Acquired Infections Therapeutic Market- Market Dynamics

Rising healthcare expenditures drive market Growth

Rising healthcare costs are expected to drive the growth of the hospital-acquired infection control market. Healthcare expenditures are the total amount spent on healthcare-related services, products, and activities over a given period, usually on an individual, community, national, or global scale. As healthcare spending rises, hospitals and healthcare facilities are preparing to allocate more resources to the adoption of advanced infection prevention technologies, which include innovative solutions such as advanced disinfection systems, smart monitoring devices, and other technologies that improve overall infection control measures. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared to 0.9% in 2022. As a result, rising healthcare expenditure will drive future growth in the hospital-acquired infection control market.

Hospital Acquired Infections Therapeutic Market- Key Insights

According to our research analyst, the global market is expected to increase at a CAGR of approximately 3.70% between 2025 and 2032.

Based on Drug Type segmentation, the antibacterial drugs category had the highest income.

Based on Infection Type segmentation, In 2024, the bloodstream infections segment dominated the market.

According to region, Europe had the most revenue in 2024.

Hospital Acquired Infections Therapeutic Market- Segmentation Analysis:

The global release liner market is divided into four groups: Drug Type, Route of Administration, Infection Type, and geography.

The market is divided into four categories based on drug type: antibacterial drugs, antifungal drugs, antiviral drugs, and other drug types. Antibacterial drugs dominated the HAI therapeutics market in 2024. This dominance is because bacteria cause the vast majority of HAIs. As a result, a large proportion of HAIs are treated with antibacterial drugs. Furthermore, antibacterial therapy is the first line of treatment for all hospital-acquired infections. All patients infected with gram-positive and gram-negative pathogens must be treated with antibiotics. Empiric antibiotic therapy should be considered first based on a variety of risk factors for multidrug-resistant bacteria. Empiric antibiotic therapy is used to prevent complications like kidney damage, pyelonephritis, and bloodstream infections. Antibacterial therapy can be as short as 7 days or as long as 14-21 days.

Based on the type of infection, the market is divided into five segments: surgical site infections, urinary tract infections, bloodstream infections, ventilator-associated pneumonia, and other hospital infections. In 2024, the bloodstream infections segment held the largest market share. Bloodstream infections, also referred to as sepsis or bacteremia, are serious infections caused by bacteria or other pathogens entering the bloodstream. They are caused by a variety of microorganisms, including bacteria, viruses, and fungi, and can lead to serious complications like septic shock, organ failure, and death. Bloodstream infections are a major cause of morbidity and mortality in hospital settings, particularly among critically ill patients.

Hospital Acquired Infections Therapeutic Market- Geographical Insights

This market is geographically diversified across Europe, the Middle East, North America, Asia Pacific, and Africa, Latin America. The regions are further divided by the nations that bring commerce. In 2024, Europe dominated the market for HAI therapeutics, and this trend is expected to continue throughout the study period. This dominance is attributed to the high prevalence of HAIs in European countries, as well as the region's increasing approvals and launches of novel HAI therapeutics. Furthermore, the increased availability of novel hospital-acquired infection therapeutics in European countries due to the local presence of major players such as GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Allergan Plc, and Bayer AG is expected to support regional growth.

The HAIs therapeutics market in Asia Pacific is expected to grow significantly during the forecast period. This increase is attributed to the rising prevalence of chronic diseases in emerging economies like India and China, which has resulted in more hospitalisations. For example, Globocan reported that approximately 4,285,033 new cancer cases were diagnosed in China in 2018. Thus, the rising rate of HAIs and hospitalisations is expected to drive demand for HAI therapeutic drugs and support regional growth.

Hospital Acquired Infections Therapeutic Market- Competitive Landscape:

Major pharmaceutical companies such as Merck & Co., Abbott, F. Hoffmann-La Roche, AbbVie, and Allergan Plc compete in the Hospital Acquired Infections (HAIs) Therapeutic Market, with a focus on developing innovative antibiotics and antimicrobial therapies. Additionally, emerging biotech firms are investigating niche treatments such as monoclonal antibodies and bacteriophage therapy. Collaborations between established companies and startups are becoming more common as a way to improve drug development and address the rising prevalence of HAIs. As antibiotic resistance spreads, competition heats up, highlighting the need for effective treatment options and better patient outcomes in healthcare settings. For instance, in April 2024, Basilea Pharmaceutica International Ltd. reached a significant milestone when the FDA approved its new bloodstream infection treatment, Zevtera. This approval is a significant strategic move for Basilea, cementing its position as a market leader in HAI therapies. Zevtera's approval will broaden treatment options for severe infections, improving patient outcomes and strengthening Basilea's market presence through innovative solutions.

Recent Developments:

In October 2023, Spartan Medical Inc. launched a new campaign to increase awareness of surgical site infections (SSIs) and their consequences throughout the United States. This strategy aims to educate healthcare professionals and patients about the risks of SSIs and the importance of prevention, resulting in increased demand for advanced infection control measures and therapeutic solutions. The campaign strengthens Spartan Medical's position in the infection control market by emphasising the company's dedication to addressing critical healthcare challenges.

In April 2022, Pfizer signed a definitive agreement to acquire ReViral, a clinical-stage biopharmaceutical company focused on developing antiviral therapies for respiratory syncytial virus (RSV). The acquisition will help Pfizer expand its presence in the antiviral therapeutics field and support its efforts to develop new treatments for RSV and other respiratory infections.

In December 2021, Merck, also known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that their antiviral drug molnupiravir has been granted Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of COVID-19. This is a significant step forward in the global effort to combat the COVID-19 pandemic, building on Merck's history of developing innovative drugs that address major health threats and improve patient outcomes.

SCOPE OF THE REPORT

This report's scope includes the following important market segments:

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Merck & Co.
  • Abbott
  • F. Hoffmann-La Roche
  • AbbVie
  • Allergan Plc
  • Eugia Pharma
  • Bayer
  • DAIICHI SANKYO COMPANY
  • Glenmark Pharmaceuticals
  • GSK
  • Hikma Pharmaceuticals
  • Melinta Therapeutics
  • Pfizer
  • Sanofi
  • Viatris
  • Others

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antibacterial drugs
  • Antifungal drugs
  • Antiviral drugs
  • Other drug types

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV)
  • Topical
  • Oral
  • Inhalation

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Surgical site infections
  • Urinary tract infections
  • Bloodstream infections
  • Ventilator-associated pneumonia
  • Other hospital infections

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Hospital Acquired Infections Therapeutic Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Hospital Acquired Infections Therapeutic Market Snippet by Drug Type
    • 2.1.2. Hospital Acquired Infections Therapeutic Market Snippet by Route of Administration
    • 2.1.3. Hospital Acquired Infections Therapeutic Market Snippet by Infection Type
    • 2.1.4. Hospital Acquired Infections Therapeutic Market Snippet by Country
    • 2.1.5. Hospital Acquired Infections Therapeutic Market Snippet by Region
  • 2.2. Competitive Insights

3. Hospital Acquired Infections Therapeutic Key Market Trends

  • 3.1. Hospital Acquired Infections Therapeutic Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hospital Acquired Infections Therapeutic Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hospital Acquired Infections Therapeutic Market Opportunities
  • 3.4. Hospital Acquired Infections Therapeutic Market Future Trends

4. Hospital Acquired Infections Therapeutic Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hospital Acquired Infections Therapeutic Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Hospital Acquired Infections Therapeutic Market Landscape

  • 6.1. Hospital Acquired Infections Therapeutic Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hospital Acquired Infections Therapeutic Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Antibacterial drugs
    • 7.1.3. Antifungal drugs
    • 7.1.4. Antiviral drugs
    • 7.1.5. Other drug types

8. Hospital Acquired Infections Therapeutic Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Intravenous (IV)
    • 8.1.3. Topical
    • 8.1.4. Oral
    • 8.1.5. Inhalation

9. Hospital Acquired Infections Therapeutic Market - By Infection Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Infection Type, 2024 & 2032 (%)
    • 9.1.2. Surgical site infections
    • 9.1.3. Urinary tract infections
    • 9.1.4. Bloodstream infections
    • 9.1.5. Ventilator-associated pneumonia
    • 9.1.6. Other hospital infections

10. Hospital Acquired Infections Therapeutic Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Hospital Acquired Infections Therapeutic Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Hospital Acquired Infections Therapeutic Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co.
    • 11.2.2. Abbott
    • 11.2.3. F. Hoffmann-La Roche
    • 11.2.4. AbbVie
    • 11.2.5. Allergan Plc
    • 11.2.6. Eugia Pharma
    • 11.2.7. Bayer
    • 11.2.8. DAIICHI SANKYO COMPANY
    • 11.2.9. Glenmark Pharmaceuticals
    • 11.2.10. GSK
    • 11.2.11. Hikma Pharmaceuticals
    • 11.2.12. Melinta Therapeutics
    • 11.2.13. Pfizer
    • 11.2.14. Sanofi
    • 11.2.15. Viatris
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us